Overview

A Study to Evaluate the Safety and Efficacy of Three Doses of a Controlled Release Formulation of Varenicline for Smoking Cessation

Status:
Withdrawn

Trial end date:
2011-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, efficacy, and tolerability of twice daily (BID) administration of three dose strengths (1.2 mg, 1.8 mg, and 2.4 mg) of varenicline controlled release (CR) tablets in adult smokers.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Varenicline